

Patent Application Attorney Docket No. 30520A

1646 July

Hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 23rd day of November 2004.

Ву	Glather Kandhahn	
	(Signature of person mailing) Heather Randhahn	
	(Typed or printed name of person)	

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Anders Berkenstam

APPLICATION SERIAL NO.: 09/143,828 : Examiner: Michael D. Pak

FILING DATE: 08/31/1998 : Group Art Unit: 1646

TITLE: NOVEL VITAMIN D RECEPTOR RELATED:

POLYPEPTIDES, NUCLEIC ACID

SEQUENCE ENCODING THE SAME AND

USES THEREOF

Hon. Commissioner for Patents

P. O. Box 1450

Alexandria, VA 22313-1450

Sir:

FILING OF FORMS PTO/SB/82 AND PTO/SB/96

The enclosed "Revocation and Power of Attorney with New Power of Attorney and Change of Correspondence Address" and "Statement Under 37 CFR 3.73(b)" are submitted herewith in connection with the above-referenced patent application.

Respectfully submitted,

Date: November 23, 2004

Pfizer Inc.

Patent Department, MS 8260-1611 Eastern Point Road Groton, Connecticut 06340 (617) 551-3223 Nicholas I. Stepchuk, Jr. Attorney for Applicant(s)

PTO/SB/82 (09-04)
Approved for use through 11/30/2005. OMB 0651-0035
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

REVOCATION OF POWER OF ATTORNEY WITH NEW POWER OF ATTORNEY AND CHANGE OF CORRESPONDENCE ADDRESS

NOV 2 6 2004

spond to a collection of information unit	ess it displays a valid Olvib Control Humber.	
Application Number	09/143,828	
Filing Date	08/31/1998	
First Named Inventor	Berkenstam, A.	
Art Unit	1646	
Examiner Name	Michael D. Pak	
Attorney Docket Number	PC30520	

I hereby revoke all previous powers of attorney given in the above-identified application.						
A Power of Attorney is submitted herewith.						
OR I hereby appoint the practitioners associated with the Customer Number: 28523						
Please change the correspondence address for the above-identified application to: The address associated with						
Customer Number: 28523 OR						
Firm or Individual Name						
Address						
City State Zip						
Country						
Telephone Fax						
l am the: Applicant/Inventor.						
Assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96)						
SIGNATURE of Applicant or Assignee of Record						
Signature ()						
Name Gregg Benson on behalf of Pfizer Inc.						
Date Minimum 16, 2004 Telephone 860-441-4901						
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.						
*Total of <u>one</u> forms are submitted.						

This collection of information is required by 37 CFR 1.36. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE NOV 2 6 2004 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PADEMAR	X	STATEMENT UNDER 37 CF	R 3.73(b)
Applican		t ai.	
			V31/1998
Entitled:			ACID SEQUENCE ENCODING THE SAME AND
	.	a Corporation	•
(Name of A	ssignee)		., corporation, partnership, university, government agency, etc.)
states that		e, and interest; or	
2. ar	assignee of less than the entire	right, title and interest.	
•••	o chain (by percentage) of its of	whership interest is%	
in the pat	ent application/patent identified a	above by virtue of either:	<u> </u>
111.4	assignment from the inventor(s he United States Patent and Tra- reof is attached.) of the patent application/patent i demark Office at Reel	dentified above. The assignment was recorded, Frame, or for which a copy
OR B. ✓ A d		of the patent application/patent id	lentified above, to the current assignee as shown
1	. From: Biovitrum AB	To: Pfizer Inc.	
	Reel <u>015353</u> , Frame <u>0</u>	in the United States Patent and T 649 , or for which	h a copy thereof is attached.
2	From: Pharmacia AB	To: Blovitrum A in the United States Patent and T	В
	Reel 014222 Fran	in the United States Patent and T ne <u>0208</u> , or for wh	rademark Office at ich a copy thereof is attached.
3.		erg, M. To: Pharmacia	
	The document was recorded	in the United States Patent and T	rademark Office at
	Reel <u>9559</u> , Frai	me <u>0981</u> , or for w	hich a copy thereof is attached.
	Additional documents in the chair	n of title are listed on a supplemen	ntal sheet
Copie:	s of assignments or other docum	ents in the chain of title are attach	ned
INO	t: A separate copy (i.e., a true co	ODV of the original assignment dov	riment(s)) must be submitted to Assignment
-	IPEP 302.08]	R Part 3, if the assignment is to b	be recorded in the records of the USPTO. See
The weder	100		
/ Ine under	signed owners title is supplied be	elow) is authorized to act on beha	If of the assignee
-	Sign		' / (nember 16, 2004
_Grego	Signa G. Berlson for Pfizer Inc.	ature	/ Date /
y	Printed or Ty	ped Name	
Assista	int General Patent Counsel, Pfizer In	c .	
	Titl		

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissionar for Patente. P.O. Box 1450, Alexandria, VA 22313-1450. FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.